申请人:IRM LLC
公开号:US08178526B2
公开(公告)日:2012-05-15
The invention provides a novel class of compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or dysregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).
该发明提供了一种新型化合物类别的公式(I),包括这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的B细胞活动相关的疾病或障碍的方法,特别是涉及肌醇1,4,5-三磷酸3-激酶B(ITPKb)异常激活的疾病或障碍。